Virax Operating Income vs Depreciation And Amortization Analysis
| VRAX Stock | USD 1.94 0.06 3.19% |
Virax Biolabs financial indicator trend analysis is much more than just breaking down Virax Biolabs Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Virax Biolabs Group is a good investment. Please check the relationship between Virax Biolabs Operating Income and its Depreciation And Amortization accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Operating Income vs Depreciation And Amortization
Operating Income vs Depreciation And Amortization Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Virax Biolabs Group Operating Income account and Depreciation And Amortization. At this time, the significance of the direction appears to have no relationship.
The correlation between Virax Biolabs' Operating Income and Depreciation And Amortization is 0.0. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Virax Biolabs Group, assuming nothing else is changed. The correlation between historical values of Virax Biolabs' Operating Income and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of Virax Biolabs Group are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Operating Income i.e., Virax Biolabs' Operating Income and Depreciation And Amortization go up and down completely randomly.
Correlation Coefficient | 0.0 |
| Relationship Direction | Flat |
| Relationship Strength | Insignificant |
Operating Income
Operating Income is the amount of profit realized from Virax Biolabs Group operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Virax Biolabs Group is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most indicators from Virax Biolabs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Virax Biolabs Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At this time, Virax Biolabs' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.30 in 2024, whereas Selling General Administrative is likely to drop slightly above 2.7 M in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 15.4K | 15.5K | 26.9K | 28.3K | Depreciation And Amortization | 1.7M | 1.0 | 103.1K | 97.9K |
Virax Biolabs fundamental ratios Correlations
Click cells to compare fundamentals
Virax Biolabs Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.